Drug Profile
Bevacizumab biosimilar - STC Biologics
Alternative Names: STC 103Latest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator STC Biologics
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Jul 2015 Discontinued - Preclinical for Cancer in USA (IV) (STC Biologics product pipeline, July 2015)